HRP970260A2 - 2,4-diaminopyrimidine derivatives - Google Patents

2,4-diaminopyrimidine derivatives

Info

Publication number
HRP970260A2
HRP970260A2 HR96107739.3A HRP970260A HRP970260A2 HR P970260 A2 HRP970260 A2 HR P970260A2 HR P970260 A HRP970260 A HR P970260A HR P970260 A2 HRP970260 A2 HR P970260A2
Authority
HR
Croatia
Prior art keywords
diaminopyrimidine derivatives
diaminopyrimidine
derivatives
Prior art date
Application number
HR96107739.3A
Other languages
English (en)
Inventor
Philippe Guerry
Henri Stalder
Pierre-Charles Wyss
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of HRP970260A2 publication Critical patent/HRP970260A2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HR96107739.3A 1996-05-15 1997-05-15 2,4-diaminopyrimidine derivatives HRP970260A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96107739 1996-05-15

Publications (1)

Publication Number Publication Date
HRP970260A2 true HRP970260A2 (en) 1998-04-30

Family

ID=8222784

Family Applications (1)

Application Number Title Priority Date Filing Date
HR96107739.3A HRP970260A2 (en) 1996-05-15 1997-05-15 2,4-diaminopyrimidine derivatives

Country Status (29)

Country Link
US (1) US5866583A (fr)
EP (1) EP0901488B1 (fr)
JP (1) JP3098259B2 (fr)
KR (1) KR100295509B1 (fr)
CN (1) CN1098260C (fr)
AR (1) AR007088A1 (fr)
AT (1) ATE227282T1 (fr)
AU (1) AU726416B2 (fr)
BR (1) BR9709251A (fr)
CA (1) CA2254117C (fr)
CO (1) CO4840509A1 (fr)
CY (1) CY2425B1 (fr)
CZ (1) CZ364698A3 (fr)
DE (1) DE69716901T2 (fr)
DK (1) DK0901488T3 (fr)
ES (1) ES2184089T3 (fr)
HR (1) HRP970260A2 (fr)
IL (1) IL126702A0 (fr)
MA (1) MA24182A1 (fr)
NO (1) NO985335L (fr)
NZ (1) NZ332481A (fr)
PE (1) PE78898A1 (fr)
PL (1) PL330277A1 (fr)
PT (1) PT901488E (fr)
TR (1) TR199802331T2 (fr)
TW (1) TW438796B (fr)
WO (1) WO1997043277A1 (fr)
YU (1) YU51498A (fr)
ZA (1) ZA973984B (fr)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998039328A1 (fr) * 1997-03-03 1998-09-11 F.Hoffmann-La Roche Ag 2,4,-diaminopyrimidines substitues
JP4174077B2 (ja) * 1997-03-03 2008-10-29 バジリア ファルマスーチカ アーゲー 置換２，４−ジアミノピリミジン
US6277860B1 (en) * 1999-10-29 2001-08-21 Pfizer Inc Furopyridine antibacterials
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
CA2528834A1 (fr) * 2003-06-13 2005-02-10 Arena Pharmaceuticals, Inc. Derives d'acide 2h-pyrazol-3- carboxylique substitues en 5 utilises comme agonistes du recepteur de l'acide nicotinique rup25 pour le traitement des dyslipidemies et des pathologies apparentees
EP1653949A4 (fr) * 2003-08-07 2009-04-22 Merck & Co Inc Carboxamides de pyrazole utilises comme inhibiteurs de la dehydrogenase-1 11-beta-hydroxysteroide
AU2004264356B2 (en) 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
DE102005062987A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln
CA2695331A1 (fr) * 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Derives de pyridinecarboxamide et de benzamide servant de ligands de taar1
RU2528406C2 (ru) * 2008-11-21 2014-09-20 Раквалиа Фарма Инк. Новое производное пиразол-3-карбоксамида, обладающее антагонистической активностью в отношении рецептора 5-нт2в
US8716280B2 (en) * 2009-01-21 2014-05-06 Basilea Pharmaceutica Ag Bicyclic antibiotics
EP2513063B1 (fr) * 2009-12-15 2013-11-06 Bayer CropScience AG Procédé de fabrication de dérivés d'acide carbonique de 1-alkyl-/1-aryl-5-pyrazol
EP2694509B1 (fr) 2011-04-05 2016-05-18 Pfizer Limited Dérivés de pyrrolo-[2,3-d]pyrimidine en tant qu'inhibiteurs des kinases associées à la tropomyosine
DE102013208484B4 (de) 2013-05-08 2018-04-26 Wirtgen Gmbh Vorrichtung zum Bearbeiten von Straßen- oder Bodenoberflächen, sowie Verfahren zum Lenken einer Straßenfräsmaschine
WO2020041556A1 (fr) * 2018-08-22 2020-02-27 The Regents Of The University Of Colorado, A Body Corporate 1h-1,2,4-triazole-3-carboxamides n-substitués, analogues de ceux-ci, et méthodes de traitement faisant appel à ceux-ci
AR117169A1 (es) * 2018-11-28 2021-07-14 Bayer Ag (tio)amidas de piridazina como compuestos fungicidas
WO2021233861A1 (fr) * 2020-05-19 2021-11-25 Bayer Aktiengesellschaft (thio)amides azabicycliques en tant que composés fongicides

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3485840A (en) * 1964-11-12 1969-12-23 Hoffmann La Roche 2,4-diamino - 5 - (2',4',5'-substituted benzyl) pyrimidines,intermediates and processes
US4515948A (en) * 1973-09-12 1985-05-07 Hoffmann-La Roche Inc. 2,4-Diamino-5-(4-amino and 4-dimethylamino-3,5-dimethoxy benzyl)pyrimidines
US4013644A (en) * 1976-03-15 1977-03-22 G. D. Searle & Co. [8 α(E), 13aβ]-5,8,13,13a-tetrahydro-2,3,10,11-tetramethoxy-8-(2-phenylethenyl)-6H-dibenzo[a,g]quinolizines and intermediates thereto
NO811630L (no) * 1980-05-29 1981-11-30 Bayer Ag Imidazoazolalkensyreamider, nye mellomprodukter for deres fremstilling, deres fremstilling og deres anvendelse som legemiddel
US4594199A (en) * 1983-09-19 1986-06-10 E. R. Squibb & Sons, Inc. Method for making phosphinic acid intermediates
WO1992008461A1 (fr) * 1990-11-14 1992-05-29 Protos Corporation Inhibition specifique de la dihydrofolate reductase et composes prevus a cet effet
NZ296532A (en) * 1994-11-24 2000-02-28 F Substituted 5-benzyl-2,4,-diaminopyrimidines
WO1996040640A1 (fr) * 1995-06-07 1996-12-19 Pfizer Inc. DERIVES DE BIPHENYL-2-ACIDE CARBOXYLIQUE-TETRAHYDRO-ISOQUINOLEINE-6-YL AMIDES, PREPARATION DE CES AMIDES ET UTILISATION EN TANT QU'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE TRIGLYCERIDE MICROSOMAL ET/OU DE LA SECRETION D'APOLIPOPROTEINES B (Apo B)
CA2238521C (fr) * 1995-12-04 2005-08-16 F. Hoffmann-La Roche Ag Diaminopyrimidines, compositions pharmaceutiques les contenant et utilisation de celles-ci en tant qu'agents antibacteriens

Also Published As

Publication number Publication date
ZA973984B (en) 1997-11-17
BR9709251A (pt) 1999-08-10
CA2254117A1 (fr) 1997-11-20
MA24182A1 (fr) 1997-12-31
WO1997043277A1 (fr) 1997-11-20
US5866583A (en) 1999-02-02
NO985335L (no) 1999-01-15
NZ332481A (en) 2000-04-28
CZ364698A3 (cs) 1999-02-17
CY2425B1 (en) 2004-11-12
JP3098259B2 (ja) 2000-10-16
EP0901488A1 (fr) 1999-03-17
ES2184089T3 (es) 2003-04-01
PE78898A1 (es) 1998-11-13
DE69716901D1 (de) 2002-12-12
KR20000011053A (ko) 2000-02-25
PT901488E (pt) 2003-03-31
IL126702A0 (en) 1999-08-17
KR100295509B1 (ko) 2001-09-17
CA2254117C (fr) 2003-03-11
JPH11511749A (ja) 1999-10-12
DE69716901T2 (de) 2003-09-18
AU2894297A (en) 1997-12-05
TR199802331T2 (xx) 1999-04-21
AR007088A1 (es) 1999-10-13
NO985335D0 (no) 1998-11-16
CO4840509A1 (es) 1999-09-27
ATE227282T1 (de) 2002-11-15
PL330277A1 (en) 1999-05-10
EP0901488B1 (fr) 2002-11-06
AU726416B2 (en) 2000-11-09
TW438796B (en) 2001-06-07
CN1218465A (zh) 1999-06-02
DK0901488T3 (da) 2003-03-03
YU51498A (en) 1999-11-22
CN1098260C (zh) 2003-01-08

Similar Documents

Publication Publication Date Title
IL127566A0 (en) Substituted 6,5-hetero- bicyclic derivatives
IL128049A0 (en) Substituted 6,6-hetero-bicyclic derivatives
IL141908A (en) 1,4-benzodiazepine derivatives
ZA97521B (en) 19-Nor-pregnene derivatives.
ZA986358B (en) Dolastatin 15 derivatives.
IL126702A0 (en) 2,4-Diaminopyrimidine derivatives
HU9802807D0 (en) 1,3,8-triazo-spiro[4,5]decan-4-on derivatives
AU1416195A (en) Substituted 1,2,3,4-tetrahydro-5-nitro pyrimidines
IL126624A0 (en) 3-descladinose-2, 3-anhydroerythromycin derivatives
AP9500731A0 (en) 1,5 benzodiazepine derivatives
GB2311779B (en) 2,3 benzodiazepine derivatives
ZA974953B (en) Substituted pyrazolylpyrazole derivatives.
ZA971167B (en) Heterocyclyl-ergoline derivatives.
CY2322B1 (en) Benzoaeguequinoline derivatives.
HRP970162A2 (en) 1,25-dihydroxy-16,22,23-trisdehydro-cholecalciferol derivatives
ZA981529B (en) Substituted 2,4-diaminopyrimidine
IL132162A0 (en) 2, 3-Epoxypropionamide derivatives
IL132162A (en) 2,3-epoxypropionamide derivatives
HUP9903369A3 (en) 8(9)-dehydroestradiol derivatives
ZA972692B (en) Pyrrolopyrrolone derivatives.
ZA977881B (en) N-benzylazolium derivatives.
EP0679651A3 (fr) Dérivés de thiadiazinone.
GB9406037D0 (en) 1,5 Benzodiazepine derivatives
ZA953056B (en) 1,5 benzodiazepine derivatives
ZA965384B (en) 4-Amino-5-oxy-2,6,6-trimethyl-2-cycloheptene compounds

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODBC Application rejected